|
|
||||||||
Departments of 1Physiology and Biophysics and 2Internal Medicine, 3Howard Hughes Medical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242; 4Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030; and 5Lung Biology Research Program, Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada
Submitted 25 January 2005 ; accepted in final form 28 July 2005
Gene transfer of CFTR cDNA to airway epithelia is a promising approach to treat cystic fibrosis (CF). Most gene transfer vectors use strong viral promoters even though the endogenous CFTR promoter is very weak. To learn whether expressing CFTR at a low level in a fraction of cells would correct Cl transport, we mixed freshly isolated wild-type and CF airway epithelial cells in varying proportions and generated differentiated epithelia. Epithelia with
20% wild-type cells generated
70% the transepithelial Cl current of epithelia containing 100% wild-type cells. These data were nearly identical to those previously obtained with CFTR expressed under control of a strong promoter in a CF epithelial cell line. We also tested high level CFTR expression using the very strong cytomegalovirus (CMV) promoter as well as the cytokeratin-18 (K18) promoter. In differentiated airway epithelia, the CMV promoter generated 50-fold more transgene expression than the K18 promoter, but the K18 promoter generated more transepithelial Cl current at high vector doses. Using functional studies, we found that with marked overexpression, some CFTR channels were present in the basolateral membrane where they shunted Cl flow, thereby reducing net transepithelial Cl transport. These results suggest that very little CFTR is required in a fraction of CF epithelial cells to complement Cl transport because transepithelial Cl flow is limited at the basolateral membrane. Thus they suggest a broad leeway in promoter strength for correcting the CF gene transfer, although at very high expression levels CFTR may be mislocalized to the basolateral membrane.
cystic fibrosis; gene therapy; promoter; cytomegalovirus; cytokeratin-18
This article has been cited by other articles:
![]() |
R. Robert, G. W. Carlile, C. Pavel, N. Liu, S. M. Anjos, J. Liao, Y. Luo, D. Zhang, D. Y. Thomas, and J. W. Hanrahan Structural Analog of Sildenafil Identified as a Novel Corrector of the F508del-CFTR Trafficking Defect Mol. Pharmacol., February 1, 2008; 73(2): 478 - 489. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Granio, C. Norez, K. J. D. Ashbourne Excoffon, P. H. Karp, M. Lusky, F. Becq, P. Boulanger, J. Zabner, and S.-S. Hong Cellular Localization and Activity of Ad-Delivered GFP-CFTR in Airway Epithelial and Tracheal Cells Am. J. Respir. Cell Mol. Biol., December 1, 2007; 37(6): 631 - 639. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Bruscia, E. C. Ziegler, J. E. Price, S. Weiner, M. E. Egan, and D. S. Krause Engraftment of Donor-Derived Epithelial Cells in Multiple Organs Following Bone Marrow Transplantation into Newborn Mice Stem Cells, October 1, 2006; 24(10): 2299 - 2308. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |